Homechevron_rightAll Peptideschevron_rightTirzepatide

verified_user

Safety data sheet

Standardized safety protocols and material specifications for professional use.

analytics

Certificate of Analysis

Purity verified via High-Performance Liquid Chromatography (HPLC) for #myo-tirzepatide-10mg

Official Product Data Sheet

Tirzepatide (10mg)

Ultra High >99.5% Purity

Vial Contents

10 mg Tirzepatide (lyophilized powder)

Includes

3 ml bacteriostatic water for reconstitution

Form

Lyophilized white powder for optimal stability

Purity

≥99%, third-party tested (COA available)

Sequence

Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys... (39 aa with C20 diacid linker)

Molecular Formula

C₂₂₅H₃₄₈N₄₈O₆₈

Molecular Mass

4813.53 g/mol

CAS No.

2023788-19-2

Solubility

Reconstitute with sterile/bacteriostatic water (3 ml for ~3.33 mg/mL)

Storage

Lyophilized refrigerated or frozen; reconstituted refrigerated at 2–8°C for up to 28 days

Authorized Resellers

Available through our trusted partners

verifiedVerified

123peptide.com

Europe

local_shipping1-3 Business Days

Buy from Partneropen_in_new

verifiedVerified

Retatrutridekopen.com

Europe

local_shipping3-5 Business Days

Buy from Partneropen_in_new

View all authorized resellersshopping_cart

Scientific Background

Tirzepatide has quickly become one of the most talked-about options for people serious about sustainable weight reduction and metabolic improvement. Its dual-receptor mechanism delivers results that many find noticeably superior to older single-pathway therapies.

Tirzepatide is a synthetic 39-amino-acid peptide engineered to simultaneously activate both GLP-1 and GIP receptors. This dual incretin action mimics natural gut hormones, leading to enhanced insulin secretion (glucose-dependent), suppressed glucagon release, slowed gastric emptying, and powerful central appetite regulation.

The molecule features strategic modifications (including Aib substitutions and a C20 fatty diacid chain) that dramatically extend its half-life to ~5 days, enabling once-weekly dosing. By engaging both GLP-1 and GIP pathways, it achieves synergistic effects: greater fat oxidation, improved insulin sensitivity, and stronger satiety signals than GLP-1-only compounds.

Intended Research Use

Substantial and sustained body weight reduction (15–22% in trials)
Powerful HbA1c and fasting glucose improvements
Appetite suppression and enhanced satiety
Improved lipid profile (↓ triglycerides, ↑ HDL)
Reduced visceral and liver fat content
Cardiometabolic risk factor benefits

menu_bookScientific Publications

article

N Engl J Med (2022)

Tirzepatide once weekly for the treatment of obesity

open_in_newhttps://pubmed.ncbi.nlm.nih.gov/35658024/

article

N Engl J Med (2021)

Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes

open_in_newhttps://pubmed.ncbi.nlm.nih.gov/34170647/

article

Lancet (2021)

Once-weekly tirzepatide versus once-daily insulin degludec (SURPASS-3)

open_in_newhttps://pubmed.ncbi.nlm.nih.gov/34370921/

article

Lancet (2021)

Tirzepatide versus insulin glargine in type 2 diabetes (SURPASS-4)

open_in_newhttps://pubmed.ncbi.nlm.nih.gov/34619105/

article

JAMA (2022)

Effect of subcutaneous tirzepatide vs placebo on glycemic control (SURPASS-5)

open_in_newhttps://pubmed.ncbi.nlm.nih.gov/35133415/

Clinical Evidence: Clinical trials (SURPASS and SURMOUNT series) consistently demonstrate 15–22% average body weight reduction at higher doses, together with HbA1c drops of 2.0–2.5% in type 2 diabetes patients. Liver fat content also decreases significantly in many participants.

warning

FOR RESEARCH USE ONLY. This product is intended for laboratory research purposes only and is not for human consumption, medical, or diagnostic use.

Possible stacks with other peptides

Synergistic combinations for enhanced research outcomes

Clinical research suggests combining Tirzepatide with complementary peptides can enhance weight management and metabolic outcomes. These combinations target multiple pathways for amplified fat-burning and appetite control effects.

Cagrilintide

arrow_forward

myo-cagrilintide-5mg

Adds amylin-like satiety enhancement for even greater appetite control and weight loss synergy.

Tesamorelin

arrow_forward

myo-tesamorelin-10mg

Targets visceral fat reduction via GH stimulation while tirzepatide drives overall mass loss.

AOD-9604

arrow_forward

myo-hgh-fragment-aod-9604-5mg

Direct lipolytic action complements tirzepatide's incretin-driven fat metabolism.

MOTS-c

arrow_forward

myo-mots-c-10mg

Mitochondrial optimization supports energy levels and endurance during caloric deficit.

schedule

Cycling Note: Schedule: Once-weekly subcutaneous injection for 12–26+ weeks. Continue for sustained weight loss and metabolic improvement.